Artificial Intelligence in Genomics Market worth $1,671 million by 2025 – Complete Analysis Of Key Players, Growth Rate, Opportunities, Challenges
Posted on 329
PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announce that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory. The companies will initially collaborate on up to 30 pharma and biotechnology drug discovery programs over the next two years.
Together, the two companies have the capacity to advance a large number of innovative AI enhanced drug discovery programs and build an industry pipeline of partnered R&D opportunities. The agreement is pump-primed by 17 chronic diseases studies that PrecisionLife completed last year, which revealed detailed patient stratifications and multiple novel druggable targets per diseas
PrecisionLife Unveils New Spin-out Synomics Taking Its Proven Analytics Platform Into Animal and Crop Health Sectors apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Artificial Intelligence in Genomics Market worth $1,671 million by 2025 - Exclusive Report by MarketsandMarkets Artificial Intelligence In Genomics Market by Offering (Software, Services),Technology (Machine Learning, Computer Vision), Functionality (Genome Sequencing, Gene Editing), Application (Diagnostics), End User (Pharma, Research) - Global Forecasts to 2025 , published by MarketsandMarkets, the global AI in Genomics market is projected to reach USD 1,671 million by 2025 from USD 202 million in 2020, at a CAGR of 52.7% between 2020 and 2025
Browse in-depth TOC on
141 - Tables
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36649899
The need to control drug development and discovery costs and time, increasing public and private investments in AI in genomics, and the adoption of AI solutions in precision medicine are driving the growth of this market. However, the lack of a skilled AI workforce and ambiguous regulatory guidelines for medica
The need to control drug development and discovery costs and time, increasing public and private investments in AI in genomics, and the adoption of AI solutions in precision medicine are driving the growth of this market. However, the lack of a skilled AI workforce and ambiguous regulatory guidelines for medical software are expected to restrain the market growth during the forecast period.
Machine learning to dominate the AI in Genomics market in 2019
Based on technology, the Artificial Intelligence in Genomics Market is segmented into machine learning and other technologies. The machine learning segment dominated this market in 2019, as pharmaceutical companies, CROs, and biotechnology companies have widely adopted machine learning for drug genomics applications. This is because machine learning can extract insights from data sets, accelerating genomic research.